Latest news

• Shire claims FDA approval for slow-cooked ADHD drug

  XR (mixed amphetamine salts) and is due to reach the US market in the third quarter of the year.

• Shire pitching at adult ADHD product launch in 2017

  Shire wants to develop a drug called SHP465 (triple-bead mixed amphetamine salts) for adult ADHD, but to satisfy the FDA will have to first carry out a trial of the ... Adults already receive treatment for ADHD off-label using drugs such as Adderall and

• Shire misses Q1 targets as Replagal sales fall

  Despite these setbacks, Shire's core attention-deficit hyperactivity disorder (ADHD) franchise delivered the goods, with Vyvanse (lisdexamfetamine) and Adderall XR (mixed amphetamine salts) doing better than expected.

• Actavis sales rise but profits slump as Lipitor effect recedes

  Notable generic launches in the year included versions of Shire's attention-deficit hyperactivity disorder (ADHD) drug Adderall XR (mixed amphetamine salts), Sanofi's anticoagulant Lovenox (enoxaparin), Sunovion Pharma's Xopenox

• Shire pays $48m to settle generic Adderall XR claims with Impax

  supply of Adderall XR (mixed amphetamine salts).